WO2005012530A3 - Antagonists and agonists of ldcam and methods of use - Google Patents

Antagonists and agonists of ldcam and methods of use Download PDF

Info

Publication number
WO2005012530A3
WO2005012530A3 PCT/US2004/023822 US2004023822W WO2005012530A3 WO 2005012530 A3 WO2005012530 A3 WO 2005012530A3 US 2004023822 W US2004023822 W US 2004023822W WO 2005012530 A3 WO2005012530 A3 WO 2005012530A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
ldcam
antagonists
methods
cfr
Prior art date
Application number
PCT/US2004/023822
Other languages
French (fr)
Other versions
WO2005012530A2 (en
Inventor
Laurent J Galibert
Wei Yan
Original Assignee
Amgen Inc
Laurent J Galibert
Wei Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Laurent J Galibert, Wei Yan filed Critical Amgen Inc
Priority to JP2006521282A priority Critical patent/JP2007500132A/en
Priority to EP04779057A priority patent/EP1648935A2/en
Priority to AU2004261941A priority patent/AU2004261941B2/en
Priority to MXPA06000974A priority patent/MXPA06000974A/en
Priority to CA2533512A priority patent/CA2533512C/en
Publication of WO2005012530A2 publication Critical patent/WO2005012530A2/en
Publication of WO2005012530A3 publication Critical patent/WO2005012530A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention pertains to agonists and antagonists of LDCAM and methods of treating disease and infection by administering one or more LDCAM antagonists or agonists. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
PCT/US2004/023822 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use WO2005012530A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006521282A JP2007500132A (en) 2003-07-25 2004-07-23 LDCAM antagonists and agonists and methods of use thereof
EP04779057A EP1648935A2 (en) 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use
AU2004261941A AU2004261941B2 (en) 2003-07-25 2004-07-23 Antagonists and agonists of LDCAM and methods of use
MXPA06000974A MXPA06000974A (en) 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use.
CA2533512A CA2533512C (en) 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49002703P 2003-07-25 2003-07-25
US60/490,027 2003-07-25

Publications (2)

Publication Number Publication Date
WO2005012530A2 WO2005012530A2 (en) 2005-02-10
WO2005012530A3 true WO2005012530A3 (en) 2005-05-12

Family

ID=34115346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023822 WO2005012530A2 (en) 2003-07-25 2004-07-23 Antagonists and agonists of ldcam and methods of use

Country Status (9)

Country Link
US (2) US7267960B2 (en)
EP (2) EP2133362B1 (en)
JP (1) JP2007500132A (en)
AT (1) ATE554108T1 (en)
AU (1) AU2004261941B2 (en)
CA (1) CA2533512C (en)
ES (1) ES2383328T3 (en)
MX (1) MXPA06000974A (en)
WO (1) WO2005012530A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
WO2006090750A1 (en) * 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
ES2625259T3 (en) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
EP2068782B1 (en) 2006-09-15 2011-07-27 Boston Scientific Limited Bioerodible endoprostheses
JP2010503491A (en) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド Bioerodible endoprosthesis with biologically stable inorganic layers
EP2081616B1 (en) 2006-09-15 2017-11-01 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
WO2008034047A2 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
DE602007010669D1 (en) 2006-12-28 2010-12-30 Boston Scient Ltd HREN FOR THIS
AU2008292854A1 (en) * 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating T cells
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
WO2009097017A2 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
WO2010101901A2 (en) 2009-03-02 2010-09-10 Boston Scientific Scimed, Inc. Self-buffering medical implants
CN102341412B (en) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 It is specific to CADM1 human antibody
ES2690199T3 (en) * 2009-07-21 2018-11-19 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
CA2954847A1 (en) * 2014-07-21 2016-01-28 Jeffrey Greve Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170022286A1 (en) * 2015-03-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of crtam agonists
WO2016181397A1 (en) * 2015-05-13 2016-11-17 Innoventions Ltd. System for inhibiting biofilm formation on catheters, other indwelling or implantable devices and other devices
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
EP3704154A1 (en) 2017-11-02 2020-09-09 Oxford BioTherapeutics Ltd Antibodies and methods of use
CN108333132A (en) * 2018-02-22 2018-07-27 哈尔滨工业大学 A kind of bio-toxicity detection method of coal chemical industrial waste water
JP2021519068A (en) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド Total non-fucosylated glycoform of antibodies produced in cell culture
BR112022005583A2 (en) 2019-09-26 2022-09-20 Amgen Inc METHODS FOR PRODUCTION OF ANTIBODY COMPOSITIONS
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
US20230398061A1 (en) * 2020-10-20 2023-12-14 The Board Of Trustees Of The Leland Stanford Junior University Injectable hydrogels for adoptive cell therapy
AR126089A1 (en) 2021-06-07 2023-09-13 Amgen Inc USE OF FUCOSIDASE TO CONTROL THE LEVEL OF AFFUCOSYLATION OF GLUCOSYLATED PROTEINS
WO2023274286A1 (en) * 2021-06-30 2023-01-05 南京圣和药业股份有限公司 Anti-crtam antibody and application thereof
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
WO2000032635A2 (en) * 1998-12-02 2000-06-08 Ixsys, Incorporated Tumor specific human monoclonal antibodies and methods of use
US20020168712A1 (en) * 1998-08-07 2002-11-14 Baum Peter Robert Molecules designated LDCAM

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPH07119760B2 (en) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション How to detect or determine a mimotope
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
ATE106249T1 (en) 1987-11-05 1994-06-15 Hybritech Inc POLYSACCHARIDE MODIFIED IMMUNOGLOBULINS WITH REDUCED IMMUNOGENIC POTENTIAL OR IMPROVED PHARMACOKINETICS.
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE3909708A1 (en) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh METHOD FOR PRODUCING BISPECIFIC ANTIBODIES
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3560609B2 (en) 1992-11-13 2004-09-02 イミュネックス・コーポレーション A novel cytokine called ELK ligand
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
KR100329409B1 (en) 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 Neural regeneration using human bone morphogenetic proteins
PT733109E (en) 1993-12-07 2006-07-31 Genetics Inst Llc MORPHOGENETIC PROTEINS OF 0SS0S PMO-12 AND PMO-13 AND THEIR COMPOSITIONS FOR TENDAO INDUCTION
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
WO1996000081A1 (en) 1994-06-24 1996-01-04 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5877155A (en) 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5686257A (en) * 1995-04-26 1997-11-11 Schering Corporation Binding compositions for mammalian T cell antigens and related reagents
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
WO1999010376A1 (en) 1997-08-22 1999-03-04 Washington University Inducible regulatory system and use thereof
AU736506B2 (en) 1997-12-03 2001-07-26 Genentech Inc. Polypeptides and nucleic acids encoding the same
US20020132981A1 (en) 1997-12-03 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
JP2003525575A (en) 1998-05-07 2003-09-02 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Secreted proteins and polynucleotides encoding them
CA2337712A1 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1124850A4 (en) 1998-10-28 2005-10-19 Human Genome Sciences Inc 12 human secreted proteins
KR20010081111A (en) 1998-12-01 2001-08-27 제넨테크, 인크. Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2354044A1 (en) 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
EP1105158A1 (en) 1999-06-30 2001-06-13 Sigma-Aldrich Company Synthetic peptide immunogens and antibodies thereto
US6596493B1 (en) * 2000-08-15 2003-07-22 The Johns Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders
AU2001296301A8 (en) 2000-09-26 2009-07-30 Human Genome Sciences Inc Nucleic acids, proteins, and antibodies
NL2002787C2 (en) 2009-04-23 2010-10-26 Medspray Xmems Bv Atomising body, atomising device, inhaler, manufacturing method of manufacturing an atomising body and assembly method for assembling an atomising device.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
US20020168712A1 (en) * 1998-08-07 2002-11-14 Baum Peter Robert Molecules designated LDCAM
WO2000032635A2 (en) * 1998-12-02 2000-06-08 Ixsys, Incorporated Tumor specific human monoclonal antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EPO Proteins [online] 9 March 1998 (1998-03-09), "Sequence 63 from Patent WO9713844.", XP002304687, retrieved from EBI accession no. EPOP:A62169 Database accession no. A62169 *

Also Published As

Publication number Publication date
EP2133362B1 (en) 2012-04-18
ES2383328T3 (en) 2012-06-20
EP1648935A2 (en) 2006-04-26
US20050058642A1 (en) 2005-03-17
AU2004261941B2 (en) 2008-04-10
US20080064104A1 (en) 2008-03-13
CA2533512A1 (en) 2005-02-10
AU2004261941A1 (en) 2005-02-10
JP2007500132A (en) 2007-01-11
US8043615B2 (en) 2011-10-25
EP2133362A1 (en) 2009-12-16
US7267960B2 (en) 2007-09-11
MXPA06000974A (en) 2006-08-31
WO2005012530A2 (en) 2005-02-10
CA2533512C (en) 2013-06-11
ATE554108T1 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
IS8485A (en) Use of substituted 2-aminotetralins in the prevention of Parkinson's disease
DE602004021585D1 (en) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE FOR USE IN THE TREATMENT OF BLOOD HIGH PRESSURE
NO20053855D0 (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
DE602004014117D1 (en) THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
PT1347971E (en) TIAHOLYLIC INHIBITORS OF TYROSINE-CINASES OF THE TEC FAMILY
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
NO20055741L (en) New chemical compounds
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401341A1 (en) APPLICATION OF OSTEOPROTEGERIN FOR THE TREATMENT AND / OR PREVENTION OF FIBROUS DISEASE
BR0314053A (en) Pyrazolopyridines and methods of obtaining and using them
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO2004110376A3 (en) Ccr-2 antagonists for treatment of neuropathic pain
MXPA04000891A (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
BRPI0409359A (en) somatostatin-dopamine chimeric analogs
MXPA05009014A (en) Ccr-3 receptor antagonists.
SE0302304D0 (en) Novel compounds
TW200509863A (en) Irradiation device for medical use
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004261941

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2533512

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006521282

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000974

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004779057

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004261941

Country of ref document: AU

Date of ref document: 20040723

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004779057

Country of ref document: EP